PBX3 and malignant colon neoplasm: Subgroup analyses showed that the beneficial effect of PBX3 hypermethylation status on CRC 10‐years OS remained significant among UICC stage III patients ([HRPS‐adjusted], 0.60 [95% CI, 0.38 to 0.95]; P = 0.029) and colon cancer patients ([HRPS‐adjusted], 0.49 [95% CI, 0.26 to 0.92]; P = 0.027).